医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

lenvatinib

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: KEYTRUDA lenvatinib pembrolizumab Plus LENVIMA

2022年02月25日

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy KEYTRUDA lenvatinib pembrolizumab Plus LENVIMA

2021年12月27日

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

バイオテクノロジーヘルスケア糖尿病腫瘍学臨床試験製薬　 TimeLine: European Commission Approves KEYTRUDA for Patients With Certain Types of Endometrial Carcinoma lenvatinib pembrolizumab Plus LENVIMA

2021年11月29日

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

バイオテクノロジーヘルスケアヘルス一般臨床試験製薬　 TimeLine: as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma European Commission Approves KEYTRUDA lenvatinib pembrolizumab Plus LENVIMA

2021年11月29日

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: in Two Different Types of Cancer lenvatinib Merck and Eisai Receive Positive pembrolizumab Plus LENVIMA

2021年10月15日